Science Explorer Back to mapMap
Discussion
Company · Oxnard · United States

Celavie Biosciences (United States)

Research works
7
▼ 87% vs 2018-21
Citations
154
20.7 per fractional work
Top-10% rate
1.8%
all institutions 10.0%
Open access
59%
world 40%
International
18%
world 18%
Celavie Biosciences (United States)

Not ranked overall: Celavie Biosciences (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Celavie Biosciences (United States) work in?

In all years, 49% of research at Celavie Biosciences (United States) is in Health Sciences, 48% in Life Sciences. Its largest fields are Medicine (49%), Neuroscience (31%), Biochemistry, Genetics and Molecular Biology (16%). It does 1.6× the world's share of Life Sciences.

Health Sciences: 4 fractional works · 49.3% of its workMedicine: 4 fractional works · 49.3% of its workSurgery: 2 fractional works · 20.3% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 4.6% of its workPhysiology: 0 fractional works · 4.4% of its workOncology: 0 fractional works · 3.8% of its workGenetics: 0 fractional works · 3.1% of its workHepatology: 0 fractional works · 3.1% of its workRheumatology: 0 fractional works · 3.0% of its workRadiology, Nuclear Medicine and Imaging: 0 fractional works · 2.4% of its workOrthopedics and Sports Medicine: 0 fractional works · 2.3% of its workTransplantation: 0 fractional works · 1.1% of its workNeurology: 0 fractional works · 0.5% of its workInternal Medicine: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.4% of its workLife Sciences: 4 fractional works · 48.5% of its workNeuroscience: 2 fractional works · 31.3% of its workDevelopmental Neuroscience: 1 fractional works · 15.2% of its workCellular and Molecular Neuroscience: 1 fractional works · 14.0% of its workCognitive Neuroscience: 0 fractional works · 2.3% of its workBiochemistry, Genetics and Molecular Biology: 1 fractional works · 15.7% of its workMolecular Biology: 1 fractional works · 14.5% of its workCell Biology: 0 fractional works · 1.1% of its workSmaller subfields together: 0 fractional works · 0.1% of its workImmunology and Microbiology: 0 fractional works · 1.5% of its workImmunology: 0 fractional works · 1.5% of its workPhysical Sciences: 0 fractional works · 2.3% of its workMaterials Science: 0 fractional works · 2.3% of its workBiomaterials: 0 fractional works · 2.3% of its workALL ITS WORKCelavieBiosciences…7fractional works, all years
Life Sciences48%Physical Sciences2%Health Sciences49%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 5 fields, with their numbers
    1. Medicine449.3%
    1. Neuroscience231.3%
    2. Biochemistry, Genetics and Molecular Biology115.7%
    3. Immunology and Microbiology01.5%
    1. Materials Science02.3%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from Celavie Biosciences (United States)?

The most cited paper from Celavie Biosciences (United States) is "Fetal derived embryonic-like stem cells improve healing in a large animal flexor tendonitis model" (Ashlee E. Watts, Amy E. Yeager, Oleg V. Kopyov et al., 2011), with 150 citations. Next come "Transplantation of Human Neural Progenitor Cells (NPC) into Putamina of Parkinsonian Patients: A Case Series Study, Safety and Efficacy Four Years after Surgery" (52) and "Safety and Feasibility of Chemoembolization with Doxorubicin-Loaded Small Calibrated Microspheres in Patients with Hepatocellular Carcinoma: Results of the MIRACLE I Prospective Multicenter Study" (43).

Most cited papers
#PaperReleasedCitations
1 Fetal derived embryonic-like stem cells improve healing in a large animal flexor tendonitis model Ashlee E. Watts, Amy E. Yeager, Oleg V. Kopyov et al. · Stem Cell Research & Therapy Open access 27 Jan 2011 150
2 Transplantation of Human Neural Progenitor Cells (NPC) into Putamina of Parkinsonian Patients: A Case Series Study, Safety and Efficacy Four Years after Surgery Ignacio Madrazo, Oleg V. Kopyov, Miguel A. Ávila‐Rodríguez et al. · Cell Transplantation Open access 21 Dec 2018 52
3 Safety and Feasibility of Chemoembolization with Doxorubicin-Loaded Small Calibrated Microspheres in Patients with Hepatocellular Carcinoma: Results of the MIRACLE I Prospective Multicenter Study Götz Martin Richter, Boris Alexis Radeleff, Christian Stroszczynski et al. · CardioVascular and Interventional Radiology Open access 22 Nov 2017 43
4 Pharmacokinetics and Antitumor Efficacy of Chemoembolization Using 40 µm Irinotecan-Loaded Microspheres in a Rabbit Liver Tumor Model Toshihiro Tanaka, Hideyuki Nishiofuku, Yasushi Hukuoka et al. · Journal of Vascular and Interventional Radiology 24 May 2014 35
5 Idarubicin-Loaded ONCOZENE Drug-Eluting Embolic Agents for Chemoembolization of Hepatocellular Carcinoma: In Vitro Loading and Release and In Vivo Pharmacokinetics Boris Guiu, Antonin Schmitt, Sven Reinhardt et al. · Journal of Vascular and Interventional Radiology 11 Oct 2014 34
All 21 most cited papers, with filters and sorting

Which research topics does Celavie Biosciences (United States) publish most on?

By volume in 2022-now: Xenotransplantation and immune response, Coronary Interventions and Diagnostics, Skin and Cellular Biology Research and Organ and Tissue Transplantation Research.

  1. 1 Xenotransplantation and immune response Surgery 0 works
  2. 2 Coronary Interventions and Diagnostics Surgery 0 works
  3. 3 Skin and Cellular Biology Research Cell Biology 0 works
  4. 4 Organ and Tissue Transplantation Research Transplantation 0 works
  5. 5 Cardiac Imaging and Diagnostics Radiology, Nuclear Medicine and Imaging 0 works
  6. 6 COVID-19 and healthcare impacts Oncology 0 works
  7. 7 Peripheral Artery Disease Management Surgery 0 works
  8. 8 Acute Myocardial Infarction Research Cardiology and Cardiovascular Medicine 0 works
  9. 9 Antiplatelet Therapy and Cardiovascular Diseases Cardiology and Cardiovascular Medicine 0 works
  10. 10 Cerebrovascular and Carotid Artery Diseases Pulmonary and Respiratory Medicine 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available59.3%not open40.7%

World: 40% of research is openly available.

with international co-authors18.2%domestic only81.8%

World: 18% is written across borders.

How has Celavie Biosciences (United States)'s research output changed?

Output in 2022-2025 was 87% lower than in 2018-2021.

still counting201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Celavie Biosciences (United States) as a percentage of every work published that year, 0.0000048% in 2022.

0.000020%0.000040%0.000060%Celavie Biosciences (United States)0.00000072% in 20242020

Fractional works of Celavie Biosciences (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Oxnard

All research institutions in Oxnard

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Celavie Biosciences (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.